Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 6:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 2,346 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Terminated Phase 3 Interventional Results available

Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study

NCT01089725
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Pain
Interventions
Placebo IV, Placebo SC, Tanezumab SC, Tanezumab IV
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
91
States / cities
Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 8, 2026, 6:14 PM EDT
Completed Phase 3 Interventional Results available

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

NCT00122382
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, placebo, methotrexate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Huntsville, Alabama • Huntington Beach, California • Colorado Springs, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2010 · Synced Oct 8, 2026, 6:14 PM EDT
Terminated Early Phase 1 Interventional

Brain Imaging in the Diabetes Prevention Program Outcomes Study

NCT03757910
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-MK-6240, 11C-PIB
Drug
Lead sponsor
José A. Luchsinger
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 8, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage

NCT02670824
View directory record Official record
Conditions
Intracerebral Hemorrhage (ICH)
Interventions
CN-105, Placebo
Drug
Lead sponsor
AegisCN LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 8, 2026, 6:14 PM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

NCT03318523
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Placebo, BIIB054
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 80 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 8, 2026, 6:14 PM EDT
Terminated Phase 2 Interventional

A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases

NCT00872482
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Cancer
Interventions
nimotuzumab
Drug
Lead sponsor
YM BioSciences
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
New Port Richey, Florida • Saint Louis Park, Minnesota • Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Jul 1, 2011 · Synced Oct 8, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Cord Blood Infusion for Children With Autism Spectrum Disorder

NCT02847182
View directory record Official record
Conditions
Autism Spectrum Disorder, ASD, Autism, PDD
Interventions
Cord Blood Infusion, Placebo
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
2 Years to 7 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 8, 2026, 6:14 PM EDT
Active, not recruiting Phase 2 Interventional

Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

NCT04476901
View directory record Official record
Conditions
Non-ischemic Dilated Cardiomyopathy
Interventions
allogeneic human mesenchymal stem cells (hMSCs), Placebo
Biological · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 80 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Stanford, California • Miami, Florida • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 8, 2026, 6:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery

NCT02509312
View directory record Official record
Conditions
Analgesia, Obstetrical, Postpartum Hemorrhage, Opioid Use, Nonsteroidals (NSAIDs)Toxicity, Coagulation Defect; Postpartum, Postoperative Pain, Ketorolac Adverse Reaction, Blood Loss, Postoperative
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 8, 2026, 6:14 PM EDT
Completed Phase 1 Interventional

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis

NCT01803867
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
rHIgM22
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Long Beach, California • Palo Alto, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2015 · Synced Oct 8, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects

NCT03430999
View directory record Official record
Conditions
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Interventions
Calmangafodipir, Placebo
Drug
Lead sponsor
Egetis Therapeutics AB (publ)
Industry
Eligibility
20 Years to 55 Years · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 8, 2026, 6:14 PM EDT
Not listed Not applicable Interventional

Does Use of Topical Lidocaine in EGD Reduce Amount of IV Midazolam and Fentanyl Required and Shorten Recovery Time

NCT02620501
View directory record Official record
Conditions
Dysphagia, GERD, Abdominal Pain
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 8, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults

NCT05721287
View directory record Official record
Conditions
Pain, Acute Pain
Interventions
SBS-1000, Placebo
Drug
Lead sponsor
Sparian Biosciences, Inc
Industry
Eligibility
18 Years to 59 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 8, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy

NCT05098067
View directory record Official record
Conditions
Hyperemesis Gravidarum, Nausea Gravidarum, Vomiting of Pregnancy
Interventions
Capsaicin Topical Cream, Metoclopramide, Ondansetron, Lactated Ringers, Intravenous
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 8, 2026, 6:14 PM EDT
Terminated Phase 3 Interventional Results available

Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

NCT05020665
View directory record Official record
Conditions
Nucleophosmin 1-mutated Acute Myeloid Leukemia
Interventions
Entospletinib, Placebo, Cytarabine, Anthracycline
Drug
Lead sponsor
Kronos Bio
Industry
Eligibility
18 Years to 74 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 8, 2026, 6:14 PM EDT
Completed Phase 3 Interventional Results available

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff

NCT04497987
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
Bamlanivimab, Placebo, Etesevimab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bentonville, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 8, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants

NCT05518734
View directory record Official record
Conditions
Pain
Interventions
VX-708, Itraconazole, Midazolam, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 8, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

NCT01030861
View directory record Official record
Conditions
Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
Interventions
Teplizumab, Placebo infusion
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
17
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 8, 2026, 6:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury

NCT01143064
View directory record Official record
Conditions
Brain Injuries
Interventions
Progesterone, Lipid emulsion without progesterone
Drug
Lead sponsor
BHR Pharma, LLC
Industry
Eligibility
16 Years to 70 Years
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
53
States / cities
Mobile, Alabama • Los Angeles, California • San Diego, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 8, 2026, 6:14 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)

NCT02942004
View directory record Official record
Conditions
Postpartum Depression
Interventions
Placebo, SAGE-547 60 μg/kg/h, SAGE-547 90 μg/kg/h
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
32
States / cities
Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 8, 2026, 6:14 PM EDT
Terminated Phase 4 Interventional Results available

The Effect of Pretreatment With Intravenous Lidocaine for Intravenous Contrast:

NCT05143489
View directory record Official record
Conditions
Pain
Interventions
Preservative Free Lidocaine, Saline
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
7 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 8, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects

NCT02601625
View directory record Official record
Conditions
Safety, Pharmacokinetics, Healthy Subjects
Interventions
Anifrolumab SC injection (300mg), Anifrolumab IV infusion (300mg), Anifrolumab SC infusion (600mg), Anifrolumab placebo SC injection (300mg), Anifrolumab placebo IV infusion (300mg), Anifrolumab placebo SC infusion (600mg)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 8, 2026, 6:14 PM EDT
Completed Phase 1 Interventional

Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia

NCT05285540
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
DT-216, DT-216 matching Placebo
Drug
Lead sponsor
Design Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 8, 2026, 6:14 PM EDT
Completed Not applicable Interventional Results available

Analgesic Efficacy of Intravenous Ibuprofen in Biliary Colic

NCT02268955
View directory record Official record
Conditions
Biliary Colic
Interventions
IV Ibuprofen, Saline
Drug
Lead sponsor
Valleywise Health
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 8, 2026, 6:14 PM EDT